88 related articles for article (PubMed ID: 10667894)
1. A retrospective study of neutropenia in HIV disease.
Moore DA; Sullivan A; Hilstead P; Gazzard BG
Int J STD AIDS; 2000 Jan; 11(1):8-14. PubMed ID: 10667894
[TBL] [Abstract][Full Text] [Related]
2. Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study.
Moore DA; Benepal T; Portsmouth S; Gill J; Gazzard BG
Clin Infect Dis; 2001 Feb; 32(3):469-75. PubMed ID: 11170956
[TBL] [Abstract][Full Text] [Related]
3. Neutropenia in patients with HIV infection: a case control study in a cohort of 1403 patients between 1982 and 1993.
Hermans P; Sommereijns B; Van Cutsem N; Clumeck N
J Hematother Stem Cell Res; 1999; 8 Suppl 1():S23-32. PubMed ID: 10596033
[TBL] [Abstract][Full Text] [Related]
4. Use of Granulocyte Colony-Stimulating Factor in a Neutropenic HIV-Infected Patient on Clozapine.
Elmore H; Lewin J; Bradley M; Sinkman A
Psychosomatics; 2016; 57(6):651-654. PubMed ID: 27720385
[No Abstract] [Full Text] [Related]
5. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients.
Keiser P; Rademacher S; Smith JW; Skiest D; Vadde V
Am J Med; 1998 Jan; 104(1):48-55. PubMed ID: 9528719
[TBL] [Abstract][Full Text] [Related]
7. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
8. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
10. Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.
Serrano-Villar S; Quereda C; Moreno A; Pérez-Elías MJ; Casado JL; Royuela A; Dronda F; Navas E; Hermida JM; Moreno S
Clin Infect Dis; 2013 Aug; 57(3):458-64. PubMed ID: 23575196
[TBL] [Abstract][Full Text] [Related]
11. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV.
Meynard JL; Guiguet M; Arsac S; Frottier J; Meyohas MC
AIDS; 1997 Jul; 11(8):995-8. PubMed ID: 9223733
[TBL] [Abstract][Full Text] [Related]
12. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
[TBL] [Abstract][Full Text] [Related]
13. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
15. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Kim S; Hughes MD; Hammer SM; Jackson JB; DeGruttola V; Katzenstein DA
AIDS Res Hum Retroviruses; 2000 May; 16(7):645-53. PubMed ID: 10791875
[TBL] [Abstract][Full Text] [Related]
16. Haematopoietic growth factors as supportive therapy in HIV-infected patients.
Hermans P
AIDS; 1995 Dec; 9 Suppl 2():S9-S14. PubMed ID: 8775801
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3.
Fillaux J; Delpierre C; Alvarez M; Jaafar A; Marchou B; Massip P; Cuzin L
Med Mal Infect; 2006 Jun; 36(6):335-9. PubMed ID: 16631330
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of neutropenia in patients with human immunodeficiency virus infection.
Farber BF; Lesser M; Kaplan MH; Woltmann J; Napolitano B; Armellino D
Infect Control Hosp Epidemiol; 1991 Jul; 12(7):429-34. PubMed ID: 1918889
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
20. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
